In conclusion, this study highlights the utility of blood‐based biomarkers, with a particular emphasis on plasma p‐tau217, in detecting Aβ/tau stages, GFAP‐mediated Aβ‐induced tau progression, and NfL‐associated non‐AD‐specific neuronal injury and cognitive decline. This evidence concerns the gene MAPT and Alzheimer disease.